Overview We are a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics. Our integrated drug creation platform combines Origin-1, our generative design model, with rapid validation using our lab-in-the-loop. We focus on underexplored mechanisms where unmet medical need is high and competition is low. We have advanced our first two programs from AI design to IND (or foreign equivalent) in around two years with a total investment of ap...
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-24 | 2025-12-31 | 0001672688-26-000068 | EDGAR | 83K words |
| 2025-03-18 | 2024-12-31 | 0001628280-25-013464 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0001628280-24-012366 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001628280-23-009908 | EDGAR | — |
| 2022-03-22 | 2021-12-31 | 0001628280-22-006925 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001672688-26-000136 | EDGAR | 55K words |
| 2025-11-12 | 2025-09-30 | 0001672688-25-000084 | EDGAR | 56K words |
| 2025-08-12 | 2025-06-30 | 0001628280-25-039938 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001628280-25-025077 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001628280-24-046862 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001628280-24-037193 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001628280-24-023062 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001628280-23-038983 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001628280-23-029197 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001628280-23-018165 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001628280-22-029092 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001628280-22-022331 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-11 | 0001672688-26-000134 | EDGAR | 3K words |
| 2026-03-24 | 0001672688-26-000066 | EDGAR | 3K words |
| 2026-03-06 | 0001672688-26-000047 | EDGAR | — |
| 2026-01-14 | 0001672688-26-000003 | EDGAR | — |
| 2025-11-12 | 0001672688-25-000082 | EDGAR | — |
| 2025-11-04 | 0001672688-25-000076 | EDGAR | — |
| 2025-08-12 | 0001628280-25-039878 | EDGAR | — |
| 2025-07-25 | 0001193125-25-165466 | EDGAR | — |
| 2025-07-08 | 0001628280-25-034544 | EDGAR | — |
| 2025-06-12 | 0001628280-25-030953 | EDGAR | — |
91 total filings indexed. 64 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001672688 |
| Ticker | ABSI |
| Exchange | Nasdaq |
| SIC | 8731: Services-Commercial Physical & Biological Research |
| Website | https://www.absci.com |
| Listed | 2021-07-22 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ABSI (~200 tokens, structured JSON with cryptographic provenance)